Author

Spyridon Michopoulos

EFFICACY AND SAFETY OF ARGON PLASMA COAGULATION (APC) STANDARD CATHETER USE, AFTER SUBMUCOSAL INJECTION FOR BARRETT’S ESOPHAGUS (BE) ABLATION
EFFICACY AND SAFETY OF ARGON PLASMA COAGULATION (APC) STANDARD CATHETER USE, AFTER SUBMUCOSAL INJECTION FOR BARRETT’S ESOPHAGUS (BE) ABLATION

Spyridon Michopoulos  et al.

THE INFLAMMATORY BOWEL DISEASE – DISK TOOL FOR ASSESSING DISABILITY IN INFLAMMATORY BOWEL DISEASE PATIENTS: VALIDATION OF THE GREEK VERSION
THE INFLAMMATORY BOWEL DISEASE – DISK TOOL FOR ASSESSING DISABILITY IN INFLAMMATORY BOWEL DISEASE PATIENTS: VALIDATION OF THE GREEK VERSION

Spyridon Michopoulos  et al.

IS ANTI-PD1-INDUCED COLITIS A DISTINCT HISTOLOGICAL SUBTYPE?
IS ANTI-PD1-INDUCED COLITIS A DISTINCT HISTOLOGICAL SUBTYPE?

Spyridon Michopoulos  et al.

THE VEDOLIZUMAB CLINICAL DECISION SUPPORT TOOL FOR CROHN'S DISEASE EFFECTIVELY PREDICTS CLINICAL REMISSION AT 54 WEEKS IN A "REAL WORLD" SETTING
THE VEDOLIZUMAB CLINICAL DECISION SUPPORT TOOL FOR CROHN'S DISEASE EFFECTIVELY PREDICTS CLINICAL REMISSION AT 54 WEEKS IN A "REAL WORLD" SETTING

Spyridon Michopoulos  et al.

MANAGEMENT AND OUTCOME OF CYTOMEGALOVIRUS INFECTION IN ULCERATIVE COLITIS PATIENTS
MANAGEMENT AND OUTCOME OF CYTOMEGALOVIRUS INFECTION IN ULCERATIVE COLITIS PATIENTS

Spyridon Michopoulos  et al.

TOFACITINIBFOR THETREATMENT OFMODERATE - SEVERE ULCERATIVE COLITIS. THE GREEK EXPERIENCE
TOFACITINIBFOR THETREATMENT OFMODERATE - SEVERE ULCERATIVE COLITIS. THE GREEK EXPERIENCE

Spyridon Michopoulos  et al.

SOMATOSTATIN ANALOGUES ARE EFFECTIVE AND SAFE IN TRANSFUSION-DEPENDENT GASTROINTESTINAL BLEEDING DUE TO ANGIODYSPLASIA: AN INDIVIDUAL PATIENT DATA META-ANALYSIS
SOMATOSTATIN ANALOGUES ARE EFFECTIVE AND SAFE IN TRANSFUSION-DEPENDENT GASTROINTESTINAL BLEEDING DUE TO ANGIODYSPLASIA: AN INDIVIDUAL PATIENT DATA META-ANALYSIS

Spyridon Michopoulos  et al.

“REAL WORLD” PRELIMINARY DATA ON THE EFFICACY AND SAFETY OF 16-WEEK INDUCTION THERAPY WITH TOFACITINIB IN PATIENTS WITH ULCERATIVE COLITIS
“REAL WORLD” PRELIMINARY DATA ON THE EFFICACY AND SAFETY OF 16-WEEK INDUCTION THERAPY WITH TOFACITINIB IN PATIENTS WITH ULCERATIVE COLITIS

Spyridon Michopoulos  et al.

THE NATURAL HISTORY OF COVID-19 IN PATIENTS WITH IBD: A NATIONWIDE STUDY BY THE HELLENIC SOCIETY FOR THE STUDY OF IBD
THE NATURAL HISTORY OF COVID-19 IN PATIENTS WITH IBD: A NATIONWIDE STUDY BY THE HELLENIC SOCIETY FOR THE STUDY OF IBD

Spyridon Michopoulos  et al.

THE NATURAL HISTORY OF COVID-19 IN VACCINATED INFLAMMATORY BOWEL DISEASE PATIENTS
THE NATURAL HISTORY OF COVID-19 IN VACCINATED INFLAMMATORY BOWEL DISEASE PATIENTS

Spyridon Michopoulos  et al.

TWELVE-MONTH OUTCOMES OF TREATMENT WITH USTEKINUMAB IN PATIENTS WITH CROHN’S DISEASE, IN A REAL-LIFE SETTING IN GREECE: INTERIM ANALYSIS OF THE ‘REASSURE’ STUDY
TWELVE-MONTH OUTCOMES OF TREATMENT WITH USTEKINUMAB IN PATIENTS WITH CROHN’S DISEASE, IN A REAL-LIFE SETTING IN GREECE: INTERIM ANALYSIS OF THE ‘REASSURE’ STUDY

Spyridon Michopoulos  et al.

PRELIMINARY DATA ON THE EFFICACY OF USTEKINUMAB IN PATIENTS WITH ULCERATIVE COLITIS IN A 'REAL-WORLD' CLINICAL SETTING
PRELIMINARY DATA ON THE EFFICACY OF USTEKINUMAB IN PATIENTS WITH ULCERATIVE COLITIS IN A 'REAL-WORLD' CLINICAL SETTING

Spyridon Michopoulos  et al.

PREGNANCY OUTCOMES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: RETROSPECTIVE DATA FROM A GREEK NATIONAL REGISTRY
PREGNANCY OUTCOMES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: RETROSPECTIVE DATA FROM A GREEK NATIONAL REGISTRY

Spyridon Michopoulos  et al.

Item 1 - 13 / 13
1